Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma

Chan Woo Kang*, Kang Won Jang*, Jinyoung Sohn¹, Sung-Moo Kim¹, Kyoung-Ho Pyo¹, Hwan Kim¹, Mi Ran Yun¹, Han Na Kang¹, Hye Ryun Kim², Sun Min Lim², Yong Wha Moon², Soonmyung Paik³,⁴, Dae Joon Kim⁷, Joo Hang Kim²,⁶ and Byoung Chul Cho²,⁶.

Author Affiliations:

1. JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Korea
2. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
3. Division of Pathology, Pittsburgh, USA
4. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea
5. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
6. Institute for Cancer Research, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
7. Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea
* These authors contributed equally to this work.

**Running Title:** Dovitinib in \( RET \)-rearranged lung adenocarcinoma.

**Keywords:** \( RET \) rearrangement, lung adenocarcinoma, dovitinib, Src, acquired resistance

**Abbreviations list**

LADC, Lung adenocarcinoma

KIF5B, kinesin family member 5B

CCDC6, coiled-coil domain containing 6

TRIM33, tripartite motif-containing 33

NCOA4, nuclear receptor coactivator 4

TKI, tyrosine kinase inhibitor

FGFR, fibroblast growth factor receptor

VEGFR, vascular endothelial growth factor receptor

PDGFR, platelet derived growth factor receptor

FAK, focal adhesion kinase

siRET, siRNA targeting \( RET \)

siSRC, siRNA targeting Src

DO, dovitinib
VA, vandetanib
SU, sunitinib
SO, sorafenib
GE, gefitinib
SA, saracatinib
PF, PF-562,271

Financial support: This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government (MEST) (2012R1A2A2A01046927 to B.C. Cho) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI13C2162 to S. Paik).

Address correspondence to: Byoung Chul Cho, M.D., Ph.D. Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Phone: 82-2-2228-8126; Fax: 82-2-393-3562; E-mail: cbc1971@yuhs.ac

Word count: 4221; Number of figures: 6 Figures; Supplementary Figure: 3 Figures; Supplementary Tables: 2 Tables

Disclosure of Potential Conflicts of Interest

The authors have no potential conflicts of interest to disclose.
Abstract

*RET* rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in *RET*-rearranged LADC has not been reported. The aims of the study are to explore anti-tumor effects and mechanisms of acquired resistance of dovitinib in *RET*-rearranged LADC. Using structural modeling and *in vitro* analysis, we demonstrated that dovitinib induced cell cycle arrest at G0/G1 phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in *RET*-rearranged LC-2/ad cells. Strong anti-tumor effect of dovitinib was observed in LC-2/ad tumor xenograft model. To identify the acquired resistance mechanisms to dovitinib, LC-2/ad cells were exposed to increasing concentrations of dovitinib to generate LC-2/ad DR cells. Gene set enrichment analysis of gene expression and phosphor kinase revealed that Src, a central gene in focal adhesion, was activated in LC-2/ad DR cells. Saracatinib, a src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells. Taken together, these findings suggest that dovitinib can be a potential therapeutic option for *RET*-rearranged LADC, in which acquired resistance to dovitinib can be overcome by targeting Src.
Introduction

Lung cancer is the most common cause of cancer death worldwide (1). Although survival of lung cancer patients still remains poor, molecular targeted therapies, which block important oncogenic pathways, have made remarkable progress over the years, particularly in lung adenocarcinoma (LADC), which is the most common histological subtype of lung cancer (2-4). Indeed, treatment with gefitinib or crizotinib in EGFR mutation-positive or ALK-rearranged advanced LADC, respectively, has led to unprecedented improvements in objective response rate and progression-free survival over cytotoxic chemotherapy (5). The prevailing concept of genomics-driven medicine based on remarkable efficacy of these targeted therapies and the expanding genomic landscape of LADC have led to a significant surge in the number of genotype-directed lung cancer trials in molecular subtypes defined by oncogenic driver mutations in PIK3CA, HER2, BRAF, and ROS1 (1).

RET encodes the tyrosine kinase receptor of growth factors belonging to the glial-derived neurotrophic factor family. Recently, RET rearrangement, specifically fusion, has emerged as a new molecular subtype in LADC (6, 7). The prevalence of RET fusions has been estimated as approximately 1.2% to 2.0% in LADC (6-11). Several RET fusions have been identified in LADC, including kinesin family member 5B (KIF5B)-RET, coiled-coil domain containing 6 (CCDC6)-RET, tripartite motif-containing 33 (TRIM33)-RET and nuclear receptor coactivator 4 (NCOA4)-RET. Among all fusion variants, KIF5B-RET is the most common type of fusion involving RET, present in approximately 90% of cases reported to date (11). RET fusion was mutually exclusive with other oncogenic driver mutations, such as EGFR, HER2,
**BRAF** or **EML4-ALK** fusion (10-13). Furthermore, expression of exogenous **KIF5B-RET** induced morphological transformation and anchorage-independent growth of NIH3T3 fibroblasts (7). These findings strongly suggest that targeted inhibition of **RET** oncogene might be a potential strategy in the treatment of **RET** fusion-positive LADC.

Small molecule tyrosine kinase inhibitors (TKIs), including vandetanib, sunitinib and sorafenib, effectively inhibited **RET** fusion-positive LADC in preclinical models (7, 8, 10, 14, 15). Therefore, several clinical trials of **RET** inhibitors are ongoing in **RET** fusion-positive LADC. Recently, treatment of cabozantinib and vandetanib, which have **RET** inhibitory activity, resulted in dramatic responses in patients with **RET** fusion-positive LADC (12, 16).

Dovitinib (TKI258) is a potent inhibitor of receptor tyrosine kinases, including fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor (VEGFR) 1-3, platelet derived growth factor receptor (PDGFR)-β, which has shown anti-tumor and anti-angiogenic effects in preclinical models of colon, breast, bladder, pancreatic, and renal cell cancers (17-19). However, anti-tumor activity of dovitinib in **RET**-rearranged LADC has not been reported, except for the fact that dovitinib inhibits the **RET** kinase at a range of 7nM in *in vitro* kinase assay (Ref: dovitinib investigator’s brochure).

Herein, we show potent anti-tumor activity of dovitinib in preclinical models of **RET**-rearranged LADC. Additionally, we report the mechanism of acquired resistance to dovitinib in **RET**-rearranged LADC.
Materials and Methods

Compounds, antibodies, and cell lines

Dovitinib was kindly provided by Novartis Institutes for Biomedical Research (Basel, Switzerland). Gefitinib, vandetanib, sorafenib, sunitinib, saracatinib, and PF-562,271 were purchased from Selleck Chemical.

Antibodies against EGFR, p-EGFR, RET, p-RET (Y905), AKT, p-AKT (S473), ERK1/2, p-ERK1/2 (T202/Y204), Cyclin D1, p21, p27, FAK, p-FAK (Y397), Src, p-Src (Y416), PDGFRβ, c-KIT, FGFR3 and integrin β1, integrin β3, integrin β4, integrin β5, integrin α4, integrin α5 were purchased from Cell Signaling Technology. Rabbit polyclonal antibody to RET (p-Y1062) (ab51103), p-FLT3 (Y589) (ab171975) was purchased from Abcam. Anti-β-actin antibody was purchased from Sigma Aldrich.

LC-2/ad cells were obtained from RIKEN in September 2013, NCI-H1299 cells and HEK293 cells were obtained from American Type Culture Collection (ATCC) in January 2013. Each cell line was cultured using the medium recommended by the suppliers and never cultured for more than 3 months. The cell lines have not been authenticated by the authors.

Plasmid constructs and transfection

The plasmids that express KIF5B-RET, CCDC6-RET, and KRAS G12V were purchased from Addgene. HEK293 cells were plated at a density of $0.5 \times 10^5$ per 60 mm dish 1 day before transfection. HEK293 cells were transfected with the
appropriate expression plasmids using Polyjet transfection reagent (SignaGen),
according to the manufacturer’s instructions. Transfected HEK293 cells were
cultured at 37 °C for 24 hr and then treated with or without dovitinib for an additional
4 hr prior to lysis.

**In silico modeling**

The structure models of RET with dovitinib, sunitinib, and vandetanib were modeled
by Glide version 5.8 (Schrödinger). All figures were drawn using PyMol software
(Schrödinger).

**Growth inhibition assay**

For MTT assays, cultured cells were seeded into 96-well plates (3,000 cells per well).
Twenty-four hours after seeding, serial dilutions of appropriate inhibitors were added
to the culture. After 72 hr, 50 µl of MTT (5 mg/ml stock solution) was added and the
plates were incubated for an additional 4 hr. The medium was discarded and the
formazan blue, which was formed in the cells, was dissolved with 100 µl DMSO. The
optical density was measured at 540 nm. Relative survival in the presence of drugs
was normalized to DMSO control cells after background subtraction. For colony
formation assays, cells were seeded into 6-well plates (2.5 x 10^4 cells per well) and
treated with the agents indicated in RPMI-1640 containing 10% FBS for 14 days.
Compound treatments were replaced at least every 3 days during the assay. After 14
days, cells were fixed in 3% paraformaldehyde in phosphate buffered saline (PBS) for 10 min at room temperature and stained with 0.5% crystal violet in 20% methanol for 20 min. Images were captured using flatbed scanner, and the cells were dissolved with 20% acetic acids in 20% methanol for 30 min. Assays were performed independently at least three times.

**Apoptosis assay and cell cycle assay**

An apoptosis assay was performed using the Annexin V-FITC Detection Kit (BD bioscience) according to the manufacturer’s protocol. For the cell cycle assay, 4.0 × 10⁵ of LC2/ad cells were fixed with cold-80% ethanol for 1 hr on ice. The cells were then centrifuged at 800 rpm for 5 min followed by re-suspension in 1 ml of PI Master Mix containing 40 μl of propidium iodide (Life Technologies), 10μl of RNase A (Sigma-Aldrich) and 950μl of PBS. After incubation at 37°C for 30 min, DNA ploidy was analyzed by flow cytometry

**Immunoblotting**

Preparation of whole cell protein lysates and Western blot analysis were described previously. Briefly, cells were then chilled on ice, washed twice with ice-cold PBS, and lysed in a buffer (Cell Signaling Technology, Beverly, MA, USA) containing 1 mM PMSF and 1X protease inhibitors (Sigma Aldrich). Protein concentrations were determined using a Bradford assay kit (Bio-Rad Laboratories). Equal amounts of
protein in cell lysates were separated by SDS-PAGE, transferred to membranes, immunoblotted with specific primary and secondary antibodies, and the blot was detected by SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific), according to the manufacturer's instructions.

**Small interfering RNA transfection**

siRNA was synthesized by Invitrogen (The sequence of siRNA listed in Supplementary Table 2) and was transfected into the cells using Lipofectamine RANiMAX (Invitrogen) according to the manufacturer’s instructions.

**Human Phospho-Kinase Array**

The Human Phospho-Kinase Array Kit (R&D Systems) was used to detect the activation of 49 different protein kinases mediating various aspects of cellular proliferation following the manufacturer's instructions. Briefly, LC-2/ad cells and LC-2/ad DR cells were plated in 10-cm dishes and cultured at 37 °C for 28 hr. After cell lysis, 500 μg of lysate was applied to a membrane-anchored phosphor kinase array and incubated at 4 °C for 24 hr. Membranes were exposed to chemiluminescent reagents and detected by X-ray film (AGFA).

**Establishment of dovitinib-resistant LC-2/ad cell line**
LC-2/ad cells were cultured in increasing concentrations of dovitinib up to 5 μmol/L to generate polyclonal resistant clones (LC-2/ad DR). After approximately 6 months, LC-2/ad DR cells with strong resistance to dovitinib (IC_{50} > 3 μmol/L) were established.

**Xenograft studies**

All animal experiments were carried out under an Institutional Animal Care and Use Committee-approved protocol and institutional guidelines for the proper and humane use of animals. Nude mice were injected subcutaneously with 5 x 10^6 LC-2/ad cells or LCD-2/ad DR cells. Mice were randomized into groups of 7 animals and treated with either vehicle, vandetanib or dovitinib (oral, qd) for the indicated duration of treatment. The length, width, and depth of the tumor mass were measured every 2 days using calipers, and tumor volume was calculated as: tumor volume = 0.5236 x length x width x depth (mm^3). The rate of change in body weight (BW) was calculated using the following formula: BW= W/W_0 x 100, where W and W_0 are the body weight on a specific experimental day and on the first day of treatment, respectively.

**Microarray analysis and Gene Set Enrichment Analysis**

Total RNA was extracted using RNeasy columns (Qiagen, Valencia, USA) according to the manufacturers’ protocol. Total RNA was amplified and purified using Target Amp-Nano Labeling Kit for Illumina Expression Bead Chip (EPICENTRE) to yield
biotinylated cRNA according to the manufacturer's instructions. We used Gene Set Enrichment analysis (GSEA) to evaluate the genes comprising a specific gene signature are coordinately up- or down –regulated between LC-2/ad and LC-2/ad DR cells. Gene signatures queried included those deposited in C2 KEGG gene sets collection in the Molecular Signatures Database (MSigDB; version 4.0; http://www.broadinstitute.org/gsea/msigdb/index.jsp). A gene set of Focal adhesion factors used in the analysis was constructed using 38 Focal adhesion core factors. The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (20) and are accessible through GEO series accession number GSE69226 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69226).

**Statistical analysis**

Quantitative results were analyzed by one-way analysis of variance (ANOVA) or t-test. Statistical significance was established for $P<0.05$
Results

Dovitinib inhibits RET kinase activity

Dovitinib, of which chemical structure was shown in Figure 1A, targets types III, IV, and V RTKs including PDGFRβ, CSF-1R, KIT, FLT3, VEGFR, TrkA, RET and FGFRs. To explore RET fusion as an additional target indication of dovitinib, we first performed in silico modeling of RET with dovitinib and two other RET-TKIs, sunitinib and vandetanib (Fig. 1B). Docking score of RET kinase complex with dovitinib, sunitinib and vandetanib were calculated using Glide (Supplementary Table 1 and Fig. 1B). Docking simulation showed almost identical docking structure for dovitinib and two other RET-TKIs. Dovitinib-RET complex exhibited high docking score (-9.16), which was comparable to those of sunitinib and vandetanib. The structure modeling suggested that dovitinib formed hydrogen bonds with A907 and Q905 sites, which are located within active site of the RET kinase. According to Novartis investigator’s brochure, dovitinib inhibited RET in nanomolar range (7nM) in vitro kinase assay. Together, these results strongly suggest that dovitinib has potential to inhibit RET kinase activity.

To determine whether dovitinib could inhibit kinase activity of the two most common type of fusions, CCDC6-RET and KIF5B-RET, we first transfected HEK293 cells with plasmids encoding each fusion variants. Cells were lysed after dovitinib treatment and exogenous expression of RET kinase tyrosine 905 (Y905) was determined by immunoblot analysis (Fig. 1C). Dovitinib suppressed the phosphorylation of Y905 in both CCDC6-RET and KIF5B-RET fusion kinases,
resulting in significant reduction of ERK1/2 phosphorylation in CCDC6-RET or KIF5B-RET plasmid-transfected HEK293 cells. However, ERK1/2 phosphorylation was unaffected by dovitinib in HEK293 cells transfected with mutant KRAS\textsuperscript{G12V} plasmids. Next, we examined whether dovitinib selectively inhibited RET activity, leading to decreased ERK1/2 phosphorylation, by transfecting either KRAS\textsuperscript{G12V} or KIF5B-RET plasmids into HEK293 cells (Fig. 1D). The ERK1/2 phosphorylation induced by KRAS\textsuperscript{G12V} transfection could not be suppressed by treatment with dovitinib, a RET-TKI (vandetanib) or a selective EGFR-TKI (gefitinib). On the other hand, dovitinib and vandetanib, but not gefitinib, potently inhibited phosphorylation of RET and ERK1/2 in KIF5B-RET transfected HEK293 cells. Taken together, these results indicate that dovitinib has ability to specifically inhibits RET kinase activity and ERK1/2 signaling mediated by RET.

Dovitinib induces cell cycle arrest and apoptosis of RET rearranged LADC via selective inhibition of RET kinase

LC-2/ad cells were recently reported to harbor the CCDC6-RET rearrangement. Silencing of RET expression by siRNA targeting RET significantly decreased phosphorylation of ERK1/2, a key molecule of RET downstream signaling, and cell viability in LC-2/ad cells (14, 15). These results indicate that CCDC6-RET plays an important role in the proliferation and survival of LC-2/ad cells.

Next, we evaluated the effect of dovitinib on the growth of the LC-2/ad cells. Compared with H1299 cells without RET rearrangement, dovitinib potently
suppressed the growth of LC-2/ad (IC_{50} \approx 0.2\mu M), indicating selective anti-tumor effects of dovitinib against RET kinase activity (Fig. 2A). Consistent with the results of MTT assays, treatment of dovitinib suppressed the phosphorylation of RET and ERK1/2 in a dose-dependent manner (Fig. 2B). Moreover, dovitinib inhibited the expression of cyclin D1 and induced p21 (Fig. 2B), which was in parallel with the fact that dovitinib significantly induced cell cycle arrest at G0/G1 phase (Fig. 2C). Furthermore, treatment of dovitinib significantly increased a subpopulation of the annexin V-positive apoptotic cells (Fig. 2D).

As dovitinib is known to target multiple tyrosine kinases, the growth suppression effect of dovitinib in LC-2/ad may not be due to selective inhibition of RET kinase. To rule out this possibility, effects of dovitinib on other known targets were assessed in immunoblotting. As shown in Supplementary Figure S1A, dovitinib inhibited RET phosphorylation at the dose of 0.01 \mu M, whereas it did not affect FLT3 phosphorylation even at 1 \mu M. The phosphorylation of FGFR and PDGFR\beta were not detected in LC-2/ad. Consistent with the immunoblot analysis, the introduction of siRET in LC-2/ad significantly suppressed the proliferation, whereas siFGFR3, siPDGFR\beta, siFLT3 and siKIT had no significant effect on cell viability (Fig. 2E and 2F).

Taken together, these results suggest that dovitinib induces cell cycle arrest and cellular apoptosis via selective inhibition of RET kinase and its downstream signaling in lung cancer cells harboring RET rearrangement.
Dovitinib inhibits growth of RET rearranged LADC more effectively than other RET-TKIs

We next compared antitumor effects of dovitinib with other known RET-TKIs, such as vandetanib, sunitinib and sorafenib, using gefitinib, a selective EGFR-TKI, as a negative control. Contrary to gefitinib, dovitinib suppressed 100% inhibition of RET phosphorylation at the dose of 1 μM. This was more evident in long-exposure blots (Fig. 3A). Moreover ERK1/2 and the expression of cyclin D1 inhibited by dovitinib, as potently as other known RET-TKIs (Fig. 3A). Notably, compared with other RET-TKIs, dovitinib exerted the most potent inhibitory effects on the proliferation of LC-2/ad cells in MTT assays (Fig. 3B). The superior antitumor activity of dovitinib to vandetanib, sunitinib and sorafenib in LC-2/ad cells became more evident through long-term (14 days) colony formation assays (Fig. 3C). Taken together, our data suggest that dovitinib inhibits growth of RET rearranged LADC at least as effectively as other known RET-TKIs.

Anti-tumor activity of dovitinib in LC-2/ad xenograft models

To evaluate anti-tumor activity of dovitinib in vivo, we tested the effects of dovitinib and vandetanib on the growth of LC-2/ad xenograft tumors established in nude mice. Mice treated with dovitinib showed remarkable tumor regression at all doses without significant weight loss at 30 mg/kg and 60 mg/kg doses of dovitinib (Fig. 4A and Supplementary Fig. S2A). Vandetanib at a dose of 50 mg/kg also produced similar efficacy, although mice were not tolerated well and experienced
significant weight loss (Supplementary Fig. S2A). In waterfall plots, the percent volume changes of the individual tumors were greater in dovitinib treatment group compared with those in vandetanib group, showing complete tumor regression (-100%) in 3 out of 7 mice treated with two different doses of dovitinib (Fig. 4B). Dovitinib suppressed phosphorylation of RET and ERK1/2 relative to vehicle treatment, as assessed by Immunoblots and immunohistochemistry of tumor tissues from xenograft (Fig. 4C and 4D). Taken together, our in vitro and in vivo findings confirm that dovitinib is effective against RET fusion-positive LADC.

**Activation of Src mediates acquired resistance to dovitinib in LC-2/ad DR cells**

In most targeted agents, acquired resistance eventually develops after an initial response (21). To identify potential mechanisms of acquired resistance to dovitinib, we established LC-2/ad DR cells with acquired resistance to dovitinib by exposing LC-2/ad cells to increasing doses of dovitinib. LC-2/ad DR cells showed strong resistance to dovitinib (IC\textsubscript{50} > 3 μmol/L; Fig. 5A). Next, LC-2/ad and LC-2/ad DR cells were subjected to genome-wide gene expression profiling using cDNA microarray. Gene-set enrichment analysis against Kyoto Encyclopedia of Genes and Genomes (KEGG) database showed that focal adhesion pathway was significantly enriched, with Src contributing significantly to the core enrichment, in LC-2/ad DR cells, as compared with LC-2/ad cells (Fig. 5B). LC-2/ad DR cells displayed higher phosphorylation level of Src and focal adhesion kinase (FAK) in phospho-kinase array than LC-2/ad cells, which was confirmed by immunoblots (Fig. 5C and 5D).
Increased Src activation in LC-2/ad DR cells led to constitutive ERK1/2 phosphorylation unresponsive to dovitinib treatment (Fig. 5D). Interestingly, contrary to LC-2/ad cells, LC-2/ad DR cells did not activate RET kinase any more, suggesting the loss of addiction to RET fusion in these cells (Fig. 5D).

Previous studies have demonstrated that Src sits on the signaling node mediating resistance to multiple anticancer agents (22). The increased activation of Src led us to hypothesize that Src activation directly mediated acquired resistance to dovitinib in LC-2/ad DR cells. To test this hypothesis, we inhibited Src activity using either saracatinib, a selective Src inhibitor, or siRNA targeting Src (siSrc) in LC-2/ad DR cells. Although dovitinib and other known RET-TKIs could not inhibit tumor growth in colony formation assays, saracatinib significantly exerted growth inhibitory effects on LC-2/ad DR cells (Fig. 6A). Furthermore, siSrc could efficiently inhibit tumor growth only in LC-2/ad DR cells (Fig. 6B). On the other hand, siRET could not inhibit tumor growth in LC-2/ad DR cells, suggesting the minimal role of RET signaling in survival of these cells (Fig. 6B). Consistent with cell viability data, inhibition of RET kinase by dovitinib or siRET abrogated ERK1/2 activity only in RET-dependent LC-2/ad cells, and inhibition of Src by saracatinib or siSrc abrogated ERK1/2 activity only in Src-dependent LC-2/ad DR cells (Fig. 6C and 6D). Finally, concurrent inhibition of RET and Src signaling did not show synergistic antitumor effect in LC-2/ad DR cells, further supporting complete loss of dependence on RET signaling for survival upon acquisition of acquired resistance to dovitinib (Fig. 6E).

Given the activation of FAK and mRNA upregulation of integrin, we hypothesized that FAK-integrin axis was involved in the Src activation. To rule out
this hypothesis, we used PF-562,271, ATP-competitive reversible inhibitor of FAK. Unexpectedly, PF-562,271 had neither anti-proliferation effect nor inhibition of downstream ERK1/2 activation in LC-2/ad DR cells (Supplementary Fig. S3A, S3B). Expressions of integrins in LC-2/ad DR cells were similar with LC-2/ad cells (Supplementary Fig. S3C).

Taken together, these data indicate an essential role of Src in mediating the acquired resistance to dovitinib in RET fusion-positive LADC.
Discussion

In our study, we evaluated and compared antitumor activity of dovitinib in RET fusion-driven LADC models. Dovitinib efficiently suppressed growth of RET-rearranged LADC in vitro and in vivo by inhibiting autophosphorylation of RET and was shown to be at least as efficacious as other known RET-TKIs, such as sorafenib, sunitinib and vandetanib. Our data provided the preclinical evidence supporting a rationale for the clinical development of dovitinib in patients with RET fusion-driven LADC. Furthermore, we found that increased activation of Src mediated acquired resistance to dovitinib by phosphorylating RET downstream effector ERK1/2 in RET fusion-positive LADC.

Given that RET rearrangement is a druggable target in LADC, a number of clinical trials have been designed to investigate the therapeutic effects of multikinase inhibitors targeting RET, such as vandetanib (trial registration ID: NCT01823068), sunitinib (NCT01829217), cabozantinib (NCT01639508) and lenvatinib (NCT01877083), in RET fusion-positive LADC. In a recent report of preliminary efficacy in patients with RET fusion-positive LADC, cabozantinib, an inhibitor of MET, vascular endothelial growth factor receptor (VEGFR) and RET, achieved partial responses in 2 patients and durable stable disease in 1 patient (12). Vandetanib, an inhibitor of VEGFR, EGFR and RET, showed a dramatic response in a patients with advanced RET fusion-positive LADC (16). Moreover, alectinib (CH5424802), which has been known to be a selective inhibitor of ALK, showed antitumor activity against RET fusion-driven LADC models by inhibiting oncogenic RET fusion signaling (23). Our data support the inclusion of dovitinib in the therapeutic armamentarium of
targeted agents currently being tested for RET fusion-positive LADC. Based on our in vitro data, the lowest effective dose of dovitinib in LC-2ad cells was 0.1 μM (Fig. 2A, 2B, S1A), which can be extrapolated to 48.25 ng/ml. In our study, dovitinib showed significant anti-tumor effect in LC-2/ad xenograft at the dose of 30 mg/kg dovitinib. The trough plasma concentration (Cmin) of 7 to 23 ng/ml (20 to 60 nM) were observed in vivo with 30 mg/kg dovitinib doses, and the corresponding Cmax and AUC values ranged from 339 to 952 ng/ml and 5540 to 9670 h•ng/ml, respectively (18). Dovitinib showed pharmacodynamics effect in this dose concentration range. This information suggests that the corresponding plasma exposures were adequate for substantial efficacy in LC-2/ad xenograft model. Moreover, dovitinib has been evaluated in human phase I studies and was shown to have Cmax 273±126 ng/ml at steady state of recommended dose (500 mg, 5 days on, 2 days off) (18, 24). These results suggest that preclinical doses tested in our study can safely be achieved in patients with RET-rearranged lung adenocarcinoma.

Targeted agents that exploit genetic vulnerabilities in human cancers have now been clinically validated as effective cancer therapies. However, clinical efficacy of these agents is limited by the rapid emergence of drug resistance, which remains a substantial challenge to the clinical management of advanced cancers (21, 25-28). To our knowledge, this is the first report on the mechanism of acquired resistance to the RET inhibitor describing a link between Src-dependent survival signal activation and drug resistance in RET fusion-positive LADC.

Src regulates many fundamental cellular processes, including cell growth, differentiation, migration and drug resistance (22, 29-32). In our study, acquisition of
acquired resistance to dovitinib is attributable to the activation of a Src-driven bypass signaling pathway. We observed marked activation and expression of Src in LC-2/ad DR cells, as compared with the LC-2/ad cells. The blockade of Src signaling by saracatinib or siSrc resulted in the marked suppression of ERK1/2 phosphorylation, suggesting a dominant role of Src on ERK1/2 activation in LC-2/ad DR cells. Consistent with these results, treatment with saracatinib and siSrc dramatically suppressed cell growth in LC-2/ad DR cells. The disappointing lack of synergy in the combined treatment of dovitinib and saracatinib may be due to the fact that survival of LC-2/ad DR cells no longer depend on the activity of RET fusion kinase (Fig. 5D and 6E). Similar to our findings, loss of addiction to mutant EGFR resulted in gain of addiction to both HER2/HER3 and PI3K/Akt signaling to acquire EGFR-TKI resistance (33).

Integrins are a family of adhesion receptors for extracellular matrix (ECM) proteins, integrins can transduce biochemical signals into the cell to regulate a variety of cellular functions, including proliferation, migration, survival and drug resistance (34-37). Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase which mediates integrin signaling pathways. Src family of cytosolic protein tyrosine kinases function intimately with FAK in integrin signaling pathways (38, 39). In our study, focal adhesion kinase (FAK) activity was increased in LC-2/ad DR cells (Fig. 5D). These data also raise the question as to whether FAK could play an important role in the enhanced Src activation, resulting in the acquisition of dovitinib resistance in LC-2/ad DR cells. However, the inhibition of FAK activity using PF-562,271 could not suppress the downstream ERK1/2 activation and LC-2/ad DR cell growth
(Supplementary Fig. S3A and S3B). As shown in Supplementary Figure S3C, protein levels of integrins in LC-2/ad DR cells were similar with LC-2/ad cells and treatment of integrinβ1 could not inhibit the cell growth in LC-2/ad DR cells (data not shown). These data suggest that integrin-mediated FAK activation may not be critically involved in acquired resistance to dovitinib in LC-2/ad DR cell. Instead, Src, as a common node downstream of multiple drug resistance pathways, might be activated by various signal inputs from specific RTKs, nonreceptor tyrosine kinases or loss of protein tyrosine phosphatase activity (29, 31). Therefore, it remains to be further studied what mediates the enhanced activity of Src.

In conclusion, our findings support that dovitinib warrants further clinical evaluation in patients with RET-rearranged LADC, and targeting Src signaling is effective in RET-rearranged LADC with acquired resistance to dovitinib.
References


Figure legends

**Figure 1, Inhibition of RET-fusion kinase activity by dovitinib**

**A,** Chemical structure of dovitinib.

**B,** X-ray structure of dovitinib with \( RET \), sunitinib with \( RET \), and vandetanib with \( RET \).

**C,** Effects of dovitinib on the phosphorylation levels of \( RET \) in HEK293 cells expressing \( CCDC6-RET \), \( KIF5B-RET \), or KRAS. Each transfected HEK293 cells were treated with DMSO (-) or dovitinib 1\( \mu \)M (DO) for 4hr. The expression levels of indicated protein levels were detected by western blot analysis using the corresponding antibodies.

**D,** Western blot analysis showing the effect of dovitinib (DO), vandetanib (VA), and gefitinib (GE) on expression of indicated proteins. Each transfected cells were treated with 1\( \mu \)M of indicated inhibitor for 4 hr.

**Figure 2, Inhibition of RET-fusion driven tumors by dovitinib.**

**A,** Relative survival of H1299 and LC-/2ad against dovitinib after 72 hr treated with dovitinib.

**B,** Western blot analysis of \( CCDC6-RET \), ERK1/2, and cyclinD1, p21, and \( \beta \)-actin in LC-2/ad cells after treated with dovitinib (DO) for 4hr.
C, LC-2/ad cells were treated with dovitinib 0.5 μM (DO) for 24 or 48 hr. Cell cycle distribution was measured by propidium iodide staining and subsequent FACS analysis. Error bars indicate mean ± SEM (n = 3). **p<0.01, vehicle (DMSO) vs. DO (dovitinib) in both 24 hr and 48 hr.

D, FACs analysis via Annexin- V/PI double-staining assay was used to observe the induction of apoptosis. After treating with DMSO or dovitinib 0.5 μM (DO) for 72 hr, cells were stained with annexin V-FITC/PI double staining. Error bars indicate mean ± SEM (n=3). *p<0.05, DMSO vs. dovitinib (DO).

E, MTT assay of siCON, siFGFR3, siPDGFRb, siFLT3, siKIT, or siRET-transfected LC-2/ad cells. Indicated siRNA-transfected LC-2/ad cells were incubated for 72 hr before treating with MTT solution.

F, Colony formation assay of siCON, siFGFR3, siPDGFRb, siFLT3, siKIT, or siRET-transfected LC-2/ad cells. Indicated siRNA-transfected LC-2/ad cells were incubated for 14 days before staining with crystal violet.

Figure 3, Differences in the cell growth inhibition efficacy of RET-fusion driven NSCLC between dovitinib and other RET inhibitors.

A, Western blot analysis of indicated markers in LC-2/ad cells after treated with dovitinib (DO), gefitinib (GE), vandetanib (VA), sunitinib (SU), or sorafenib (SO) for 4 hr.
B, MTT assays of LC-2/ad. Cells were treated with 1μM sorafenib (SO), 1μM sunitinib (SU), 1μM vandetanib (VA), or 1μM dovitinib (DO) for 72 hr, and cell viability was determined using MTT (5ug/ml) solution by measuring the absorbance at 540nm in a microplate reader. Means are derived from five replicate (n=3). Error bars indicate mean ± SE of three replicates. *P < 0.05, vandetanib (VA) versus dovitinib (DO); **P < 0.01, ***P < 0.001, dovitinib (DO) versus sunitinib (SU) or sorafenib (SO) in LC-2/ad cells, respectively.

C, Colony formation assay of LC-2/ad cells. Cells were grown in the absence or presence of 0.5μM of indicated inhibitor for 14 days. All cells were fixed, stained with crystal violet (0.005%), represent quantification.

**Figure 4, Anti-tumor activity of dovitinib against RET fusion-driven tumors.**

A, Mice bearing LC-2/ad cells were treated with vehicle only (Vehicle), dovitinib (DO 30mg/kg), dovitinib (DO 60mg/kg), or vandetanib (VA 50mg/kg) for 32days. Average percent change in tumor volume relative to initial tumor volume is shown. Error bars represent SEM. ***P < 0.0001 for vehicle (Vehicle) vs. dovitinib 30mg/kg (DO 30mg/kg) treatment group.

B, Waterfall plots showing the percent change in volume (relative to initial tumor volume) for the individual tumors in each treatment group. Maximum regression tumors for each group are indicated.
C, Mice bearing LC-2/ad cells expressing CCDC6-RET were orally administered a dose of 0 (Vehicle), 30mg/kg, or 60mg/kg dovitinib (DO), and 50 mg/kg vandetanib (VA). Tumors were collected and lysed at 6hr postdosing. The expression levels of phospho-RET, RET, phospho-ERK, ERK, and β-actin were detected by western blot analysis using the appropriate antibodies.

D, Immunohistochemical (IHC) analysis of LC-2/ad xenograft tumor samples. Mice were orally administered a dose of 0 (vehicle), or 60 (dovitinib 60mg/kg) for 6hr and sacrificed, and tumors were stained with indicated antibodies. Photos shown are representative fields in each group in low and high magnification. Scale bars in the main images and in the insets indicate 100 and 50 μM, respectively.

Figure 5, Src hyperactivation in acquired dovitinib-resistant cells.

A, MTT assay comparing cell proliferation of indicated parental LC-2/ad cells and their corresponding acquired dovitinib-resistant LC-2/ad DR cells upon treatment with dovitinib for 72 hr.

B, The GSEA demonstrating a significant enrichment of the set of focal adhesion pathway genes among significantly differentially expressed genes between LC-2/ad and LC-2/ad DR cells.
C, The phosphorylation state was detected by R&D Systems Proteome Profiler Phospho-Kinase Array in LC-2/ad or LC-2/ad DR. Key activated kinase are indicated (FAK and Src)

D, Lysates from LC-2/ad and LC-2/ad DR cells were evaluated by western blotting to determine total and phosphorylated protein levels from the arrays in (C)

Figure 6, Loss of dependency on RET-fusion and gain of dependency on Src in dovatinib-resistant cells.

A, Colony formation assay of LC-2/ad DR cells. Cells were grown in the absence or presence of 0.5μM dovatinib (DO), 0.5μM vandetanib (VA), 0.5μM sunitinib (SU), 0.5μM sorafenib (SO), or 0.5μM saracatinib (SA) for 14 days. All cells were fixed, stained with crystal violet (0.005%).

B, Colony formation assay of LC-2/ad and LC-2/ad DR cells. Cells were transfected with indicated siRNA and grown for 14 days. All cells were fixed, stained with crystal violet (0.005%).

C, Western blot analysis assessing the effect of 1μM dovatinib (DO), 1μM saracatinib (SA), or combination treatment on LC-2/ad and LC-2/ad DR cells. Cells were treated indicated inhibitor(s) for 4 hr. Lysates were evaluated by western blotting with the indicated antibodies.
D, Western blot analysis of assessing the dependency, whether cell survival is mediated by CCDC6-RET or Src. Cells were transfected with siCON, siRET, or siSrc for 72 hr. Lysates were evaluated by western blotting with the indicated antibodies.

E, MTT assay of single or combination treatment of 1µM dovitinib (DO) and 1µM saracatinib (SA) in LC-2/ad and LC-2/ad DR cells. LC-2/ad and LC-2/ad DR cells were incubated for 72hr with indicated inhibitors before treating with MTT solution. Error bars indicate mean ± SE of three replicates. ***P < 0.001, dovitinib (DO) or saracatinib (SA) treated LC-2/ad versus LC-2/ad DR; ns, saracatinib (SA) treated LC-2/ad DR versus combination treated LC-2/ad DR.
Figure 2

A

Relative survival (%)

\[ \text{H1299} \]
\[ \text{LC-2/ad} \]

DO (μM)

0 0.03 0.1 0.3 1 3 10

B

<table>
<thead>
<tr>
<th>DO (μM)</th>
<th>p-RET(Y905)</th>
<th>RET</th>
<th>p-ERK1/2</th>
<th>ERK</th>
<th>Cyclin D1</th>
<th>p21</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

% of cells

24h 48h

G2/M S G0/G1

DO

- + - +

D

DMSO DO

Annexin V-FITC

% of apoptotic cells

DMSO DO

E

Relative survival (%)

siCON siFGFR3 siPDGFRb

siFLT3 siKIT siRET

F

siCON siFGFR3 siPDGFRb

siFLT3 siKIT siRET

Downloaded from mct.aacrjournals.org on April 19, 2017. © 2015 American Association for Cancer Research.
Figure 3

A

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>DO</th>
<th>GE</th>
<th>VA</th>
<th>SU</th>
<th>SO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration</td>
<td>0.3</td>
<td>1</td>
<td>0.3</td>
<td>1</td>
<td>0.3</td>
<td>1</td>
</tr>
<tr>
<td>p-RET(Y905) short</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-RET(Y905) long</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-EGFR(Y1086)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-ERK1/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERK1/2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cyclinD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Relative survival (%)

DMSO | SO | SU | VA | DO

C

DMSO | DO | VA | SU | SO | GE
Figure 6

(A) Relative survival (%) of LC-2/ad DR treated with DMSO, DO, VA, SU, SO, and SA.

(B) Cell morphology of LC-2/ad and LC-2/ad DR treated with siCON, siRET, and siSrc.

(C) Western blot analysis of LC-2/ad and LC-2/ad DR treated with DO, SA, CON, RET, and Src, showing p-RET(Y905), RET, Integrin β1, p-FAK(Y397), FAK, p-Src, Src, p-ERK1/2, ERK1/2, and β-actin.

(D) Western blot analysis of LC-2/ad and LC-2/ad DR treated with CON, RET, Src, and siRNA, showing p-RET(Y905), RET, p-Src(Y416), Src, p-ERK1/2, ERK1/2, and β-actin.

(E) Relative survival (%) of LC-2/ad and LC-2/ad DR treated with DO and SA, showing a statistical difference (*** p < 0.001, ns = not significant).
Molecular Cancer Therapeutics

Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma


Mol Cancer Ther Published OnlineFirst July 24, 2015.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0350

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/07/29/1535-7163.MCT-15-0350.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.